Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEF-IMPACT: Ceftriaxone vs Cefotaxime on Resistant Enterobacteriaceae
NCT03922919Phase 4Unknown
- Sponsor
- CHU de Besançon
- Start
- Apr 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cefotaxime in bacterial infection (2 arms), sponsored by CHU de Besançon. Primary endpoint: Frequency of occurrence of digestive carrying of 3rd generation cephalosporin-resistant enterobacteriaceae (EB C3G-R) at 30 days. Status: unknown.
02
Drugs
cefotaxime
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03922919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922919.